Francois Nader

Insider

First SEC filing: April 30, 2020 · Latest: April 30, 2020

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 15 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

15 other filings hidden

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
April 1, 2026	TECX	A	20,400	—	—	20,400 Direct	—	Acquired	(price as of 2026-08-20)
April 30, 2025	MRNA	A	12,174	—	—	12,174 Direct	—	Acquired	(price as of 2026-08-20)
April 30, 2025	MRNA	A	6,378	—	—	6,378 Direct	—	Acquired	(price as of 2026-08-20)
May 6, 2024	MRNA	A	7,557	—	—	7,557 Direct	—	Acquired	(price as of 2026-08-20)
May 3, 2023	MRNA	A	6,134	—	—	6,134 Direct	—	Acquired	(price as of 2026-08-20)
May 10, 2022	MRNA	M 10b5-1	23,100	—	—	16,620 Direct	-58.16%	Disposed	(price as of 2026-08-20)
May 10, 2022	MRNA	S	3,196	$136.10	$434,976	20,607 Direct	-13.43%	Disposed	5.2% (price as of 2026-08-20)
May 10, 2022	MRNA	M 10b5-1	23,100	$18.87	$435,897	23,803 Direct	+3285.92%	Acquired	659.1% (price as of 2026-08-20)
April 28, 2022	MRNA	A	5,415	—	—	5,415 Direct	—	Acquired	(price as of 2026-08-20)
April 28, 2022	MRNA	M	703	—	—	0 Direct	-100.00%	Disposed	(price as of 2026-08-20)
April 28, 2022	MRNA	M	703	—	—	703 Direct	—	Acquired	(price as of 2026-08-20)
April 28, 2021	MRNA	A	4,081	—	—	4,081 Direct	—	Acquired	(price as of 2026-08-20)
April 28, 2021	MRNA	A	703	—	—	703 Direct	—	Acquired	(price as of 2026-08-20)
April 29, 2020	MRNA	A	18,270	—	—	18,270 Direct	—	Acquired	(price as of 2026-08-20)
Dec. 10, 2019	MRNA	A	17,889	$18.87	$337,565	17,889 Direct	—	Acquired	659.1% (price as of 2026-08-20)
Dec. 10, 2019	MRNA	A	39,720	$18.87	$749,516	39,720 Direct	—	Acquired	659.1% (price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
April 1, 2026	TECX	Stock Option (Right to Buy)	Common Stock (20,400)	$30.78	March 31, 2036	20,400	Acquired
April 30, 2025	MRNA	Restricted Stock Units	Common Stock (12,174)	—	—	12,174	Acquired
April 30, 2025	MRNA	Stock Option (Right to Buy)	Common Stock (6,378)	$28.54	April 30, 2035	6,378	Acquired
May 6, 2024	MRNA	Stock Option (Right to Buy)	Common Stock (7,557)	$122.13	May 6, 2034	7,557	Acquired
May 3, 2023	MRNA	Stock Option (Right to Buy)	Common Stock (6,134)	$130.14	May 3, 2033	6,134	Acquired
May 10, 2022	MRNA	Stock Option (Right to Buy)	Common Stock (23,100)	$18.87	Dec. 10, 2029	23,100	Disposed
April 28, 2022	MRNA	Stock Option (Right to Buy)	Common Stock (5,415)	$142.52	—	5,415	Acquired
April 28, 2022	MRNA	Restricted Stock Units	Common Stock (703)	$0.00	—	703	Disposed
April 28, 2021	MRNA	Stock Option (Right to Buy)	Common Stock (4,081)	$178.68	April 28, 2031	4,081	Acquired
April 28, 2021	MRNA	Restricted Stock Units	Common Stock (703)	$0.00	—	703	Acquired
April 29, 2020	MRNA	Stock Option (Right to Buy)	Common Stock (18,270)	$46.37	April 29, 2030	18,270	Acquired
Dec. 10, 2019	MRNA	Stock Option (Right to Buy)	Common Stock (17,889)	$18.87	Dec. 10, 2029	17,889	Acquired
Dec. 10, 2019	MRNA	Stock Option (Right to Buy)	Common Stock (39,720)	$18.87	Dec. 10, 2029	39,720	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).